Aera Technology Recognized as One of “50 Providers to Watch” by Spend Matters
17.10.2022 15:00:00 CEST | Business Wire | Press Release
Aera Technology, the Decision Intelligence company, today announced it has been recognized on the Spend Matters “50 Providers to Watch” list as a fast-rising innovator in the procurement and supply chain market.
Purpose-built for Decision Intelligence, the Aera Decision Cloud™ enables companies to harness the data inside their enterprise software systems and digitize, augment, and automate decision making to respond to change and improve agility. Aera Decision Cloud understands how a business works, makes real-time recommendations, predicts outcomes, and takes action autonomously.
Aera bridges the gap between supply chain and procurement, connecting procurement, demand, inventory, order fulfillment, logistics, sales and marketing, and more — in one integrated platform — to execute fast, accurate decisions and achieve holistic business goals. Procurement teams gain a transactional procurement system with a supplier collaboration capability sitting right on the Aera Decision Cloud platform to easily apply Decision Intelligence to manage spend and supply in real time.
“Aera’s solution addresses a critical business area, the decision-making process with a mix of analytics, AI, orchestration, and configurability capabilities. Customers can develop actionable intelligence to automate and improve their decision-making processes by leveraging the solution’s connectivity. Because it covers multiple business functions, it potentially allows customers to break silos and connect different parts of the organization. Actions can be automated, supervised or manual, and performed by internal users or suppliers,” said Bertrand Maltaverne, Sr. Analyst (Supplier Management and Sourcing), Spend Matters.
“It’s an honor to be recognized by Spend Matters as a '50 to Watch’ company for our procurement innovation,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. “At Aera, we’re making end-to-end supply management a reality by providing a fully transactional environment to automate procurement decisions in real time. We’re empowering procurement teams with the technologies and tools to manage supply chain risk, reduce costs, and improve business performance — at the speed required today.”
Here are a few procurement decisions being augmented and automated by Aera Decision Cloud:
- How to prevent raw material orders with zero demand?
- Can demand be consolidated to get the best price?
- How to prevent purchase price variance (PPV) from happening?
- What material requirements planning (MRP) action messages like Expedites, Defers, or Cancels to execute and which ones to ignore?
- How to predict if critical suppliers will be late before the delivery date?
- Which alternate supplier to select if the existing supplier is flagged as a risk?
- When should customer shipments be expedited due to a predicted production delay?
- How to renegotiate payment terms and discounts across contracts to increase cash flow gain?
- And more . . .
For more information about how Aera is transforming procurement, visit www.aeratechnology.com/skills/procurement.
About Spend Matters
Spend Matters is the leading solution intelligence source for procurement and supply chain professionals. Combining deep technology analysis and tailored advisory services with daily news coverage and subscription research, Spend Matters is trusted by CPOs, consultants, investors and solution providers alike as their procurement technology intelligence partner.
About Aera Technology
Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005024/en/
Contact information
Zoe Kine
Ph: 415-497-5285
Email: zoe.kine@aeratechnology.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom